Cover Image
市場調查報告書

PharmaPoint:前列腺癌症 - 全球醫藥品市場預測與市場分析

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 611827
出版日期 內容資訊 英文 413 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:前列腺癌症 - 全球醫藥品市場預測與市場分析 PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年11月27日 內容資訊: 英文 413 Pages
簡介

主要7個國家 (美國,法國,德國,義大利,西班牙,英國,日本) 的前列腺癌症的治療藥市場,預計從2016年的77億美元,到2026年擴大到137億美元。預計市場2016年∼2026年以約6%的年複合成長率成長。

本報告提供前列腺癌症的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,促進因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 分類/分期
  • 症狀
  • 預後
  • QOL

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢與轉變
  • 預測手法
  • 流行病學預測
  • 討論

第6章 疾病的管理

  • 診斷概要
  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 競爭評估

  • 概要
  • 第2代荷爾蒙療法
  • 標靶治療
  • 化療
  • 治療疫苗
  • 第1代荷爾蒙療法
  • 骨治療

第8章 未滿足需求和機會的評估

第9章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 免疫療法
  • 第2代荷爾蒙療法
  • 標靶治療
  • 第1代荷爾蒙療法
  • 骨治療
  • 開發的初期階段的有潛力的藥劑
  • 其他

第10章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Astellas Pharma Inc.
    • AstraZeneca
    • Bayer
    • Clovis Oncology
    • Johnson & Johnson
    • Pfizer
    • Roche
    • Sanofi

第11章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

目錄
Product Code: GDHC163PIDR

Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized PCa can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon'sProvenge (sipuleucel-T), Sanofi's Jevtana (cabazitaxel), Johnson & Johnson's (J&J's) Zytiga (abiraterone acetate), Astellas/Pfizer's Xtandi (enzalutamide), and Bayer's Xofigo (radium 223 dichloride).

It is estimated that the value of the prostate cancer (PCa) market in 2016 was about $7.7B across the 7MM. This market is defined as sales of major branded drugs commonly prescribed for PCa patients across the 7MM, excluding bone therapies. Over half of these sales, or about $4.5B (59%), were generated in the US, with the 5EU representing the next largest region by sales, estimated to be at around $2.1B (over 27%). Japan contributed the smallest proportion of sales to the global PCa market, with 2016 sales of just over $1B (about 13.9%).

By 2026, itis projected that the PCa sales will rise to about $13.7B in the 7MM, at a Compound Annual Growth Rate (CAGR) of about 6%.

Major drivers of the growth of the PCa market over the forecast period include -

  • A rapidly aging population, resulting in PCa incident case increases in the markets covered in this report. Overall, across the 7MM, the diagnosed incidence of PCa is expected to increase by an Annual Growth Rate (AGR) of 1.7% from 2016-2026.
  • The anticipated label extensions of Johnson & Johnson (J&J)'s Zytiga and Astellas/Pfizer's Xtandi into hormone-sensitivePCa (HSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Xtandi has become an established presence in the PCa treatment algorithm, and its extended use in multiple PCa patient segments, and its continued patent protection, ensures that it will be the market-leading PCa drug by the end of the forecast period in 2026.
  • The launch of nine new premium-priced therapies for the treatment of PCa by 2026. GlobalData expects the launch of eight pipeline agents for castration-resistant prostate cancer (CRPC), and one for the treatment of localized PCa. In addition, weexpects label extensions for all second-generation hormonal agents in the treatment of HSPC.

The report "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026", provides the key metrics for prostate cancer in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report during the forecast period from 2016 to 2026.

In particular, this report provides the following -

  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AB Science, AbbVie, Advantagene, Amgen, Aptevo Therapeutics, Asana BioSciences

Scope

  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 11

2 Prostate Cancer: Executive Summary 13

  • 2.1 Value of Prostate Cancer Market to Increase Two-Fold By 2026 14
  • 2.2 Xtandi to Become the Undisputed Leader in the Global Prostate Cancer Market 16
  • 2.3 Prostate Cancer Treatment Landscape to Undergo Dramatic Change 18
  • 2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine 18
  • 2.5 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response 20
  • 2.6 What Do the Physicians Think? 20

3 Introduction 23

  • 3.1 Catalyst 23
  • 3.2 Related Reports 24
  • 3.3 Upcoming Related Reports 24

4 Disease Overview 25

  • 4.1 Etiology and Pathophysiology 25
    • 4.1.1 Etiology 25
    • 4.1.2 Pathophysiology 26
    • 4.1.3 Biomarkers 27
  • 4.2 Classification or Staging Systems 29
  • 4.3 Symptoms 31
  • 4.4 Prognosis 31
  • 4.5 Quality of Life 31

5 Epidemiology 33

  • 5.1 Disease Background 33
  • 5.2 Risk Factors and Comorbidities 33
  • 5.3 Global and Historical Trends 35
    • 5.3.1 US 36
    • 5.3.2 5EU 37
    • 5.3.3 Japan 37
  • 5.4 Forecast Methodology 37
    • 5.4.1 Sources Used 38
    • 5.4.2 Forecast Assumptions and Methods 43
  • 5.5 Epidemiological Forecast for Prostate Cancer (2016-2026) 52
    • 5.5.1 Diagnosed Incident Cases of Prostate Cancer 52
    • 5.5.2 Age-Specific Incident Cases of Prostate Cancer 53
    • 5.5.3 Incident Cases by Stage at Diagnosis 54
    • 5.5.4 Incident Cases by Risk of Biochemical Recurrence 55
    • 5.5.5 10-Year Diagnosed Prevalent Cases of Prostate Cancer 56
    • 5.5.6 10-Year Prevalent CRPC Cases 57
    • 5.5.7 10-Year Prevalent Metastatic Prostate Cancer Cases 58
    • 5.5.8 10-Year Prevalent mCRPC Cases with HRD Mutations 59
  • 5.6 Discussion 60
    • 5.6.1 Epidemiological Forecast Insight 60
    • 5.6.2 Limitations of Analysis 62
    • 5.6.3 Strengths of Analysis 62

6 Disease Management 63

  • 6.1 Diagnosis Overview 63
  • 6.2 Treatment Overview 66
    • 6.2.1 Treatment Guidelines and Leading Prescribed Drugs 66
    • 6.2.2 Clinical Practice 67
  • 6.3 US 90
    • 6.3.1 Diagnosis 90
    • 6.3.2 Clinical Practice 92
  • 6.4 France 94
    • 6.4.1 Diagnosis 95
    • 6.4.2 Clinical Practice 95
  • 6.5 Germany 98
    • 6.5.1 Diagnosis 98
    • 6.5.2 Clinical Practice 99
  • 6.6 Italy 102
    • 6.6.1 Diagnosis 102
    • 6.6.2 Clinical Practice 103
  • 6.7 Spain 105
    • 6.7.1 Diagnosis 105
    • 6.7.2 Clinical Practice 105
  • 6.8 UK 107
    • 6.8.1 Screening and Diagnosis 107
    • 6.8.2 Clinical Practice 108
  • 6.9 Japan 111
    • 6.9.1 Diagnosis 111
    • 6.9.2 Clinical Practice 112

7 Competitive Assessment 115

  • 7.1 Overview 115
  • 7.2 Second-Generation Hormonal Therapies 117
    • 7.2.1 Zytiga (Abiraterone Acetate) 117
    • 7.2.2 Xtandi (Enzalutamide) 127
  • 7.3 Targeted Therapies 139
    • 7.3.1 Xofigo (Radium 223 Dichloride) 139
  • 7.4 Chemotherapies 146
    • 7.4.1 Jevtana (Cabazitaxel) 146
  • 7.5 Therapeutic Vaccines 151
    • 7.5.1 Provenge (Sipuleucel-T) 151
  • 7.6 First-Generation Hormonal Therapies 160
    • 7.6.1 Zoladex (Goserelin Acetate) 160
    • 7.6.2 Lupron Depot (Leuprolide Acetate) 164
    • 7.6.3 Eligard (Leuprolide Acetate) 167
    • 7.6.4 Trelstar (Triptorelin Pamoate) 171
    • 7.6.5 Vantas (Histrelin Acetate) 174
    • 7.6.6 Firmagon (Degarelix) 177
    • 7.6.7 Casodex (Bicalutamide) 182
  • 7.7 Bone Therapies 186
    • 7.7.1 Zometa (Zoledronic Acid) 186
    • 7.7.2 Xgeva (Denosumab) 189

8 Unmet Needs and Opportunity Assessment 193

  • 8.1 Overview 193
  • 8.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 195
    • 8.2.1 Unmet Need 195
    • 8.2.2 Gap Analysis 195
    • 8.2.3 Opportunity 197
  • 8.3 Therapeutic Options for Non-Metastatic CRPC 198
    • 8.3.1 Unmet Need 198
    • 8.3.2 Gap Analysis 198
    • 8.3.3 Opportunity 199
  • 8.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance and Agents Able to Overcome Resistanceto Available Therapies 200
    • 8.4.1 Unmet Need 200
    • 8.4.2 Gap Analysis 201
    • 8.4.3 Opportunity 202
  • 8.5 Identification of New Targets and Positive Predictive Biomarkers of Response 203
    • 8.5.1 Unmet Need 203
    • 8.5.2 Gap Analysis 204
    • 8.5.3 Opportunity 205

9 Pipeline Assessment 207

  • 9.1 Overview 207
  • 9.2 Promising Drugs in Clinical Development 213
  • 9.3 Immunotherapies 216
    • 9.3.1 ProstAtak (Aglatimagene Besadenovec) 216
    • 9.3.2 Stapuldencel-t (DCVAC/PCa) 223
    • 9.3.3 ITK-1 229
    • 9.3.4 Tecentriq (Atezolizumab) 234
  • 9.4 Second-Generation Hormonal Therapies 239
    • 9.4.1 Apalutamide (ARN-509) 239
    • 9.4.2 Darolutamide (ODM-201) 248
  • 9.5 Targeted Therapies 256
    • 9.5.1 Masitinib (AB1010) 256
    • 9.5.2 Lynparza (Olaparib) 260
    • 9.5.3 Rubraca (Rucaparib Camsylate) 268
    • 9.5.4 Ipatasertib (GDC-0068) 274
  • 9.6 First-Generation Hormonal Therapies 281
    • 9.6.1 Relugolix (TAK-385) 281
  • 9.7 Promising Drugs in Early-Stage Development 287
    • 9.7.1 Targeting the P13K/AKT/mTOR Pathway 287
    • 9.7.2 Immunotherapies 288
    • 9.7.3 Prostate-Specific Membrane Antigen-Targeted Therapies 293
    • 9.7.4 Hormonal Therapies 297
  • 9.8 Other Drugs in Development 300

10 Current and Future Players 303

  • 10.1 Overview 303
  • 10.2 Trends in Corporate Strategy 307
  • 10.3 Company Profiles 310
    • 10.3.1 Astellas 310
    • 10.3.2 AstraZeneca 312
    • 10.3.3 Bayer 314
    • 10.3.4 Clovis Oncology 316
    • 10.3.5 Johnson & Johnson 318
    • 10.3.6 Pfizer 321
    • 10.3.7 Roche 323
    • 10.3.8 Sanofi 325

11 Market Outlook 326

  • 11.1 Global Markets 326
    • 11.1.1 Forecast 326
    • 11.1.2 Drivers and Barriers - Global Issues 330
  • 11.2 US 331
    • 11.2.1 Forecast 331
    • 11.2.2 Key Events 333
    • 11.2.3 Drivers and Barriers 334
  • 11.3 5EU 335
    • 11.3.1 Forecast 335
    • 11.3.2 Key Events 337
    • 11.3.3 Drivers and Barriers 338
  • 11.4 Japan 340
    • 11.4.1 Forecast 340
    • 11.4.2 Key Events 342
    • 11.4.3 Drivers and Barriers 343

12 Appendix 344

  • 12.1 Bibliography 344
  • 12.2 Abbreviations 379
  • 12.3 Methodology 386
    • 12.3.1 Forecasting Methodology 386
    • 12.3.2 Diagnosed Prostate Cancer Patients 386
    • 12.3.3 Percent Drug-Treated Patients 387
    • 12.3.4 Drugs Included in Each Therapeutic Class 387
    • 12.3.5 Launch and Patent Expiry Dates 387
    • 12.3.6 General Pricing Assumptions 389
    • 12.3.7 Individual Drug Assumptions 391
    • 12.3.8 Generic Erosion 402
  • 12.4 Primary Research - KOLs Interviewed for This Report 403
  • 12.5 Primary Research - Prescriber Survey 407
  • 12.6 About the Authors 408
    • 12.6.1 Analyst 408
    • 12.6.2 Therapy Area Director 408
    • 12.6.3 Epidemiologist 409
    • 12.6.4 Epidemiology Reviewers 409
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology 410
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy 411
  • 12.7 About GlobalData 412
  • 12.8 Contact Us 412
  • 12.9 Disclaimer 413

List of Tables

  • Table 1: Prostate Cancer: Key Metrics in Seven Major Pharmaceutical Markets 13
  • Table 2: Stage Definitions for PCa 29
  • Table 3: NCCN Risk-Category Classification System for PCa 30
  • Table 4: Risk Factors and Comorbidities for Prostate Cancer 34
  • Table 5: AJCC Staging of Prostate Cancer 38
  • Table 6: Risk Category Definitions 44
  • Table 7: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026 53
  • Table 8: 7MM, 10-Year Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026 57
  • Table 9: Treatment Guidelines for Prostate Cancer 66
  • Table 10: Most-Prescribed Drugs for Prostate Cancer by Drug Class in the Global Markets in 2016 67
  • Table 11: Country Profile - US 90
  • Table 12: Country Profile - France 94
  • Table 13: Country Profile - Germany 98
  • Table 14: Country Profile - Italy 102
  • Table 15: Country Profile - Spain 105
  • Table 16: Country Profile - UK 107
  • Table 17: Country Profile - Japan 111
  • Table 18: Leading Branded Treatment for PCa, 2017 116
  • Table 19: Product Profile - Zytiga 118
  • Table 20: Efficacy of Zytiga in Chemotherapy-Naive mCRPC 123
  • Table 21: Efficacy of Zytiga in Chemotherapy-Resistant mCRPC 123
  • Table 22: Results of the LATITUDE Trial of Zytiga 124
  • Table 23: Zytiga SWOT Analysis, 2017 126
  • Table 24: Product Profile - Xtandi 127
  • Table 25: Efficacy of Xtandi in Chemotherapy-Naive mCRPC 134
  • Table 26: Efficacy of Xtandi in Chemotherapy-Resistant mCRPC 135
  • Table 27: Xtandi SWOT Analysis, 2017 137
  • Table 28: Product Profile - Xofigo 139
  • Table 29: Efficacy of Xofigo in mCRPC 144
  • Table 30: Xofigo SWOT Analysis, 2017 145
  • Table 31: Product Profile - Jevtana 146
  • Table 32: Efficacy of Jevtana as Second-Line Treatment Post-Docetaxel Failure in mCRPC 148
  • Table 33: Jevtana SWOT Analysis, 2017 150
  • Table 34: Product Profile - Provenge 151
  • Table 35:Efficacy of Provenge in mCRPC 156
  • Table 36: Provenge SWOT Analysis, 2017 158
  • Table 37: Product Profile - Zoladex 160
  • Table 38:Efficacy of Zoladex in mCRPC 162
  • Table 39:Efficacy of Zoladex as Neoadjuvant/Adjuvant Treatment 162
  • Table 40: Zoladex SWOT Analysis, 2017 163
  • Table 41: Product Profile - Lupron Depot 164
  • Table 42: Lupron Depot SWOT Analysis, 2017 166
  • Table 43: Product Profile - Eligard 167
  • Table 44:Efficacy of Eligard in Advanced PCa 169
  • Table 45: Eligard SWOT Analysis, 2017 170
  • Table 46: Product Profile - Trelstar 171
  • Table 47:Efficacy of Trelstar in Advanced PCa 172
  • Table 48: Trelstar SWOT Analysis, 2017 173
  • Table 49: Product Profile - Vantas 174
  • Table 50: Vantas SWOT Analysis, 2017 176
  • Table 51: Product Profile - Firmagon 177
  • Table 52:Efficacy of Firmagon in Advanced PCa 180
  • Table 53: Firmagon SWOT Analysis, 2017 181
  • Table 54: Product Profile - Casodex 182
  • Table 55: Casodex SWOT Analysis, 2017 184
  • Table 56: Product Profile - Zometa 186
  • Table 57:Efficacy of Zometa in Advanced PCa 187
  • Table 58: Zometa SWOT Analysis, 2017 188
  • Table 59: Product Profile - Xgeva 189
  • Table 60:Efficacy of Xgeva in Advanced mCRPC 191
  • Table 61: Xgeva SWOT Analysis, 2017 192
  • Table 62: Product Profile - ProstAtak 216
  • Table 63:Efficacy of ProstAtak as Adjuvant Treatment in Combination with Radiotherapy in Localized PCa 219
  • Table 64: ProstAtak SWOT Analysis, 2017 221
  • Table 65: Product Profile - Stapuldencel-t 223
  • Table 66:Efficacy of Stapuldencel-t in mCRPC 225
  • Table 67:Results from the Randomized Phase II Study of Stapuldencel-t in mCRPC 226
  • Table 68: Stapuldencel-t SWOT Analysis, 2017 228
  • Table 69: Product Profile - ITK-1 229
  • Table 70:Efficacy Results from the Phase II Study of ITK-1 in mCRPC 231
  • Table 71: ITK-1 SWOT Analysis, 2017 233
  • Table 72: Product Profile - Tecentriq 234
  • Table 73: Tecentriq SWOT Analysis, 2017 238
  • Table 74: Product Profile - Apalutamide 239
  • Table 75:Efficacy of Apalutamide in nmCRPC 243
  • Table 76:Efficacy of Apalutamide in mCRPC 244
  • Table 77: Apalutamide SWOT Analysis, 2017 246
  • Table 78: Product Profile - Darolutamide 248
  • Table 79:Efficacy of Darolutamide in nmCRPC 252
  • Table 80: Darolutamide SWOT Analysis, 2017 254
  • Table 81: Product Profile - Masitinib 256
  • Table 82: Masitinib SWOT Analysis, 2017 259
  • Table 83: Product Profile - Lynparza 260
  • Table 84:Efficacy of Lynparza in mCRPC 264
  • Table 85: Lynparza SWOT Analysis, 2017 266
  • Table 86: Product Profile - Rubraca 268
  • Table 87: Rubraca SWOT Analysis, 2017 273
  • Table 88: Product Profile - Ipatasertib 274
  • Table 89:Efficacy of Ipatasertib in mCRPC 278
  • Table 90: Efficacy of Ipatasertib in mCRPC According to PTEN Status 278
  • Table 91: Ipatasertib SWOT Analysis, 2017 280
  • Table 92: Product Profile - Relugolix 281
  • Table 93:Efficacy of Relugolix in HNPC 284
  • Table 94: Relugolix SWOT Analysis, 2017 286
  • Table 95: Early-Stage Agents Targeting the P13K/AKT/mTOR Pathway 287
  • Table 96: Immune Checkpoint Inhibitors in Early-Stage Development for mCRPC 290
  • Table 97: PSMA-Targeted Therapeutics in Early-Stage Development for mCRPC 293
  • Table 98: Hormonal Therapies in Early-Stage Development for mCRPC 297
  • Table 99: Drugs in Development for PCa, 2017, Part 1 300
  • Table 100: Drugs in Development for PCa, 2017, Part 2 301
  • Table 101: Drugs in Development for PCa, 2017, Part 3 302
  • Table 102: Key Companies in the PCa Market in the 7MM, 2016-2026 305
  • Table 103: Astellas' PCa Portfolio Assessment, 2017 311
  • Table 104: AstraZeneca's PCa Portfolio Assessment, 2017 313
  • Table 105: Bayer's PCa Portfolio Assessment, 2017 315
  • Table 106: Clovis Oncology's PCa Portfolio Assessment, 2017 317
  • Table 107: J&J's PCa Portfolio Assessment, 2017 320
  • Table 108: Pfizer's PCa Portfolio Assessment, 2017 322
  • Table 109: Roche's PCa Portfolio Assessment, 2017 324
  • Table 110: Sanofi's PCa Portfolio Assessment, 2017 325
  • Table 111: Prostate Cancer Market - Global Drivers and Barriers, 2016-2026 330
  • Table 112: Key Events Impacting Sales for Prostate Cancer in the US, 2016-2026 333
  • Table 113: Prostate Cancer Market - Global Drivers and Barriers in the US, 2016-2026 334
  • Table 114: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2016-2026 337
  • Table 115: Prostate Cancer Market - Global Drivers and Barriers in the 5EU, 2016-2026 338
  • Table 116: Prostate Cancer Market in the 5EU - Country-Specific Barriers in the 5EU, 2016-2026 339
  • Table 117: Key Events Impacting Sales for Prostate Cancer in Japan, 2016-2026 342
  • Table 118: Prostate Cancer Market - Global Drivers and Barriers in Japan, 2016-2026 343
  • Table 119: Key Historical and Projected Launch Dates for Prostate Cancer 388
  • Table 120: Key Historical and Projected Patent Expiry Dates for Prostate Cancer 389
  • Table 121: Average Body Weight Across the 7MM 390
  • Table 122: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 407
Back to Top